Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, today announced financial results …
Peregrine Pharmaceuticals (NASDAQ:PPHM) announced that its Board of Directors has declared a quarterly cash dividend payment on the Company’s 10.50% Series E Convertible Preferred …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, announced positive new data from …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, today announced the presentation of …
On August 24, Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) announced two new clinical collaborations to expand on the company’s previous immuno-oncology combinations or drugs that fight …
AstraZeneca plc (ADR) (NYSE:AZN) and Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, …
Roth Capital’s healthcare analyst Joseph Pantginis weighed in with a favorable report on Peregrine Pharmaceuticals (NASDAQ:PPHM), after the company released its fiscal fourth-quarter and full-year 2015 results, posting EPS …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on developing novel investigational products that help harness the body’s own immune system to fight cancer, …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on developing novel investigational products that help harness the body’s own immune system to fight cancer, announced …
Roth Capital analyst Joseph Pantginis weighed in with some commentary on Peregrine Pharmaceuticals (NASDAQ:PPHM) after the company generated a preclinical data set supporting the immune …
